The increased awareness of the differences in biological activity of the tw
o enantiomers of a chiral drug has raised the demand for enantiomerically p
ure products, particularly in the pharmaceutical industry. Simulated moving
-bed chromatography can be used for the separation of the two enantiomers o
f a chiral molecule, which is feasible at all production scales, from labor
atory to pilot to production plant. The use of non-enantioselective synthes
is of racemic mixtures and simulated moving-bed enantiomer separation might
make the development process of a new chiral drug substantially shorter an
d cheaper.